Artisan Partners Limited Partnership buys $506,162,374 stake in DexCom (DXCM)

DexCom (DXCM) : Artisan Partners Limited Partnership scooped up 1,008,260 additional shares in DexCom during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 5,591,101 shares of DexCom which is valued at $506,162,374.DexCom makes up approximately 1.02% of Artisan Partners Limited Partnership’s portfolio.

Other Hedge Funds, Including , Comerica Bank sold out all of its stake in DXCM during the most recent quarter. The investment firm sold 3,687 shares of DXCM which is valued $333,784.Blackrock Japan Ltd reduced its stake in DXCM by selling 3,147 shares or 65.86% in the most recent quarter. The Hedge Fund company now holds 1,631 shares of DXCM which is valued at $147,654. Acrospire Investment Management sold out all of its stake in DXCM during the most recent quarter. The investment firm sold 100 shares of DXCM which is valued $9,066. Vigilant Capital Management added DXCM to its portfolio by purchasing 161 company shares during the most recent quarter which is valued at $13,625.

DexCom opened for trading at $90.34 and hit $92.25 on the upside on Tuesday, eventually ending the session at $92.09, with a gain of 1.69% or 1.53 points. The heightened volatility saw the trading volume jump to 5,58,137 shares. Company has a market cap of $7,725 M.

On the company’s financial health, DexCom reported $-0.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.12. The company had revenue of $137.30 million for the quarter, compared to analysts expectations of $132.54 million. The company’s revenue was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.

Many Wall Street Analysts have commented on DexCom. Company shares were Reiterated by The Benchmark Company on Aug 3, 2016 to “Buy”, Firm has raised the Price Target to $ 106 from a previous price target of $86 .

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.